Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late Ad26-ZEBOV booster after prior ChAd3-EBO Z/MVA-EBO Z vaccination in Senegal
ISRCTN15434137Phase 2Completed
- Sponsor
- Oxford Tropical Research Ethics Committee
- Start
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ad26.ZEBOV in Ebola virus disease (EVD), sponsored by Oxford Tropical Research Ethics Committee. Primary endpoints: Ebola GP-specific IgG by ELISA at 1 year and Ebola GP-specific T-cell cytokine response by ex vivo interferon-gamma ELISPOT at 1 year. Started Oct 2019; status: completed.
02
Drugs
Ad26.ZEBOV
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on ISRCTN15434137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15434137.